HC Wainwright & Co. Reiterates Buy on TScan Therapeutics, Maintains $15 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on TScan Therapeutics (NASDAQ:TCRX) and maintained a price target of $15.
August 13, 2024 | 12:27 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on TScan Therapeutics and maintained a price target of $15.
The reiteration of a Buy rating and the maintenance of a $15 price target by a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100